A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...
(Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly (NYSE:LLY)'s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to ...